Presently, treatment of ER-expressing (ER+) breast cancers by anti-estrogen drugs is the standard of care, with survival benefit even in very early breast cancers, as shown by the NSABP B-14 clinical trial in node-negative ER+ patients [1]. Here, ESR1 is linked to breast carcinoma.